Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Western blot [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NB100-1883 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NB100-1883, RRID:AB_10000967
- Product name
- Goat Polyclonal Osteopontin/OPN Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified.
- Reactivity
- Human, Mouse
- Host
- Goat
- Isotype
- IgG
- Vial size
- 0.1 mg
- Concentration
- 0.5 mg/ml
- Storage
- Store at -20C. Avoid freeze-thaw cycles.
Submitted references Osteopontin does not mitigate cisplatin ototoxicity or nephrotoxicity in adult mice.
Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.
A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.
Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.
Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.
Schmitt NC, Rubel EW
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2013 Oct;149(4):614-20
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2013 Oct;149(4):614-20
Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.
Horak CE, Lee JH, Elkahloun AG, Boissan M, Dumont S, Maga TK, Arnaud-Dabernat S, Palmieri D, Stetler-Stevenson WG, Lacombe ML, Meltzer PS, Steeg PS
Cancer research 2007 Aug 1;67(15):7238-46
Cancer research 2007 Aug 1;67(15):7238-46
A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.
Alonso SR, Tracey L, Ortiz P, Pérez-Gómez B, Palacios J, Pollán M, Linares J, Serrano S, Sáez-Castillo AI, Sánchez L, Pajares R, Sánchez-Aguilera A, Artiga MJ, Piris MA, Rodríguez-Peralto JL
Cancer research 2007 Apr 1;67(7):3450-60
Cancer research 2007 Apr 1;67(7):3450-60
Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.
Kolb A, Kleeff J, Guweidhi A, Esposito I, Giese NA, Adwan H, Giese T, Büchler MW, Berger MR, Friess H
Cancer biology & therapy 2005 Jul;4(7):740-6
Cancer biology & therapy 2005 Jul;4(7):740-6
Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.
Kolb A, Kleeff J, Guweidhi A, Esposito I, Giese NA, Adwan H, Giese T, Büchler MW, Berger MR, Friess H
Cancer biology & therapy 2005 Jul;4(7):740-6
Cancer biology & therapy 2005 Jul;4(7):740-6
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Osteopontin/OPN Antibody [NB100-1883] - Staining of MOLT4 lysate (35ug protein in RIPA buffer). Detected by chemiluminescence.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Osteopontin/OPN Antibody [NB100-1883] - Staining of lysates of cell line MOLT4 (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.
